Nektar Therapeutics (Nektar)(NASDAQ: NKTR) is a stage-clinical biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by appliying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amegen, Merck, Pfizer and UCB Pharma, etc. The company has developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. Exubera was also recognized as the most innovative diabetes medicine of 2006 in Germany.